CRESCENT BIOPHARMA, INC.
Crescent Biopharma, Inc. (Nasdaq Capital Market: ticker symbol not specified in provided text) is a clinical-stage biotechnology company focused on developing transformative oncology therapies for solid tumors. The company was incorporated in Delaware in 2003 under the former name GlycoMimetics, Inc. and underwent a… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CRESCENT BIOPHARMA, INC. does
In the company’s own words
Crescent Biopharma, Inc. (Nasdaq Capital Market: ticker symbol not specified in provided text) is a clinical-stage biotechnology company focused on developing transformative oncology therapies for solid tumors. The company was incorporated in Delaware in 2003 under the former name GlycoMimetics, Inc. and underwent a reverse recapitalization transaction with Pre-Merger Crescent in 2025, subsequently converting to a Cayman Islands incorporation.
The company operates through two primary development strategies. First, it is advancing CR-001, a PD-1 x VEGF bispecific antibody designed to combine immune checkpoint inhibition with angiogenesis inhibition in a single molecule. CR-001 is engineered to incorporate the targeting, binding cooperativity, and pharmacokinetics of ivonescimab, a clinical-stage competitor molecule that demonstrated superior progression-free survival compared to pembrolizumab in the HARMONi-2 trial. The company initiated a global Phase 1/2 trial called ASCEND in the first quarter of 2026, enrolling patients across up to eight solid tumor types including hepatocellular carcinoma, biliary tract cancer, gastric cancer, colorectal cancer, endometrial carcinoma, cervical cancer, ovarian cancer, and non-small cell lung cancer.
Second, Crescent is building a portfolio of antibody-drug conjugates (ADCs) designed to deliver cytotoxic payloads to cancer cells. CR-002 is a PD-L1-directed ADC with a topoisomerase inhibitor payload intended for PD-L1-expressing tumors. CR-003, also known as SKB105, is an integrin beta-6 (ITGB6)-directed ADC acquired through an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. outside of Greater China.
The company's strategy emphasizes combining CR-001 with its ADC candidates to create synergistic combination therapies. Crescent has licensed intellectual property from Paragon Therapeutics, Inc. and maintains a partnership with Kelun that enables parallel clinical development of CR-001 in both Chinese and non-Chinese patient populations. The company anticipates initiating CR-002 monotherapy trials in the second half of 2026 and CR-003 trials in the first quarter of 2026, with the first CR-001 ADC combination trial expected in the second half of 2026.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1253689
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CRESCENT BIOPHARMA, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CRESCENT BIOPHARMA, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CRESCENT BIOPHARMA, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CRESCENT BIOPHARMA, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CRESCENT BIOPHARMA, INC.'s last four quarterly filings that the numbers alone won't show?”